CRIS Current Research Information System

CASADEI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.892
EU - Europa 2.171
AS - Asia 916
AF - Africa 154
SA - Sud America 6
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.145
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.887
IT - Italia 505
SE - Svezia 473
GB - Regno Unito 427
DE - Germania 302
VN - Vietnam 281
CN - Cina 279
IN - India 145
SG - Singapore 137
IE - Irlanda 111
FR - Francia 74
RU - Federazione Russa 61
TG - Togo 54
CI - Costa d'Avorio 38
ZA - Sudafrica 37
JO - Giordania 34
UA - Ucraina 34
EE - Estonia 30
FI - Finlandia 25
CH - Svizzera 24
NG - Nigeria 24
BG - Bulgaria 23
BE - Belgio 17
AT - Austria 13
ES - Italia 10
PL - Polonia 10
IR - Iran 7
NL - Olanda 7
HK - Hong Kong 6
CA - Canada 5
JP - Giappone 5
LB - Libano 5
PK - Pakistan 5
RO - Romania 5
AU - Australia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
HR - Croazia 3
IL - Israele 3
MK - Macedonia 3
BR - Brasile 2
CL - Cile 2
MY - Malesia 2
PE - Perù 2
TR - Turchia 2
BD - Bangladesh 1
BY - Bielorussia 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 6.145
Salva come PNG Salva come JPEG
Città #
Fairfield 387
Southend 373
Chandler 330
Ashburn 244
Houston 183
Woodbridge 173
Dong Ket 166
Seattle 156
Wilmington 151
Princeton 136
Ann Arbor 134
Singapore 120
Cambridge 117
Bologna 115
Dublin 111
Berlin 62
Lomé 54
Redmond 43
Abidjan 38
Beijing 38
Hyderabad 38
New York 38
Westminster 38
Nanjing 37
Bremen 36
Amman 34
Jinan 31
San Diego 30
Milan 28
Turin 28
Padova 27
Abeokuta 23
Helsinki 22
Rome 22
Santa Clara 22
Bern 21
Boardman 21
Changsha 18
Shenyang 18
Brussels 17
Florence 17
Sofia 17
Dearborn 16
Tianjin 16
Des Moines 14
Hebei 14
Los Angeles 14
Saint Petersburg 14
Olalla 13
Jacksonville 11
Jiaxing 11
Catania 10
Nanchang 10
Taizhou 10
Hangzhou 9
London 9
Vienna 9
Guangzhou 8
Paris 8
Norwalk 7
Parma 7
Warsaw 7
Adelfia 6
Bühl 6
Hong Kong 6
Ravenna 6
Redwood City 6
Medford 5
Mülheim 5
Toronto 5
Vicenza 5
Zhengzhou 5
Amsterdam 4
Chicago 4
Haikou 4
Imola 4
Modena 4
Monmouth Junction 4
Naples 4
Nuoro 4
Phoenix 4
Pune 4
Reggio Emilia 4
Riolo Terme 4
Tokyo 4
Verona 4
Bari 3
Boydton 3
Copenhagen 3
Council Bluffs 3
Dallas 3
Falls Church 3
Frankfurt am Main 3
Hefei 3
Lanzhou 3
Lappeenranta 3
Las Vegas 3
Nuremberg 3
San Felice sul Panaro 3
San Lazzaro di Savena 3
Totale 4.084
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 195
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 175
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 158
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 147
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 144
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 143
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 142
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 136
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 135
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 134
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 128
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 125
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 119
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 118
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 114
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 112
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 112
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 111
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 111
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 110
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 109
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 107
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 106
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 105
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 104
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 102
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 100
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 99
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 98
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 96
Vemurafenib mucosal side-effect. 95
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 95
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia 92
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 91
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 91
Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) 81
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 80
Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides) 78
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 75
null 75
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 74
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 74
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 74
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 71
Impressive continuous complete response after mogamulizumab in a heavily pretreated Sézary syndrome patient 71
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 70
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 70
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 65
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 58
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report 57
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 56
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 56
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas 56
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 55
Spontaneous remission of follicular lymphoma 52
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity 49
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 46
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 42
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 41
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 41
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient 38
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 36
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review 34
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors 33
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 33
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 31
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 28
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 27
Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers 27
Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report 26
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 26
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 26
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 25
Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation 24
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 22
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 22
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 21
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 18
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi 18
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 16
Follicular lymphoma: the diminishing role of chemotherapy. 14
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 13
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 11
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 11
Mogamulizumab-associated rashes, their presentation and prognostic significance: a single-centre retrospective case series analysis 10
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 10
Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study 10
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy 10
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 9
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 9
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 8
Endobronchial Presentation of Hodgkin Lymphoma Responding to Pembrolizumab: A Case Report 7
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study 7
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report 6
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 2
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 2
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 2
Totale 6.398
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.058
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.058
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.197 0 31 6 58 167 150 169 185 197 102 55 77
2020/2021794 107 46 25 15 14 16 22 39 106 44 43 317
2021/20221.226 121 56 59 106 97 62 23 93 44 118 270 177
2022/20231.678 142 223 117 202 124 125 55 138 260 53 129 110
2023/2024739 56 98 67 88 64 90 37 54 24 66 39 56
2024/2025304 169 135 0 0 0 0 0 0 0 0 0 0
Totale 6.398